CN102357195B - Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof - Google Patents
Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof Download PDFInfo
- Publication number
- CN102357195B CN102357195B CN 201110346271 CN201110346271A CN102357195B CN 102357195 B CN102357195 B CN 102357195B CN 201110346271 CN201110346271 CN 201110346271 CN 201110346271 A CN201110346271 A CN 201110346271A CN 102357195 B CN102357195 B CN 102357195B
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- parts
- medicine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating cardiovascular and cerebrovascular diseases, and a preparation method and application of the medicinal composition. The medicinal composition can prolong coagulation time, reduce cholesterol levels and contribute to reducing the formation rate of thrombus and atherosclerosis, can be used for treating cerebrovascular diseases such as cerebral ischemia, cerebral thrombosis, cerebral embolism and the like, and cardiovascular diseases such as coronary disease, hypertension, hyperlipaemia, atherosclerosis, myocardial ischemia, arrhythmia, heart failure, stenocardia, myocardial infarction and the like, particularly has good treatment effect when used for continued treatment on patients suffering the cardiovascular and cerebrovascular diseases after emergency treatment, and is a new choice for clinical medication.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cerebrovascular and cardiovascular disease and its production and use.
Background technology
Cerebrovascular and cardiovascular disease have become first killer of human health, and its M ﹠ M surpasses neoplastic disease already and leaps to the first, and most patients need take medicine all the life.Cerebrovascular disease is the one group of disease that causes brain tissue damage because of brain blood supply obstacle, and based on middle-older patient, most of patients shows as hemiplegia, speech disorder etc.Such disease is many to be inducement with blood vessel wall pathological changes atherosclerosis, hyperlipidemia, diabetes, hypertension, thrombocytosis, coronary heart disease, poisoning etc.Common cerebrovascular disease has transient ischemic attack, cerebral thrombosis, cerebral infarction, apoplexy etc.In International Classification of Diseases, cerebrovascular disease is divided into nervous system disease, during treatment, should dredge cerebrovascular or prevent intracranial hemorrhage, and the cranial nerve that also needs protection simultaneously reduces the infringement of ischemic state to cranial nerve.
Cardiovascular disease is a series of diseases that relate to blood circulation, and blood circulation refers to hemophoric organ and tissue in the human body, mainly comprises heart, blood vessel (tremulous pulse, vein, blood capillary), generally all is relevant with arteriosclerosis.Such disease is many to be inducement with hypertension, hyperlipidemia, diabetes, overworked etc.Common cardiovascular disease has atherosclerosis, coronary heart disease and hypertension, myocardial infarction, angina pectoris, heart failure, arrhythmia, hyperlipidemia etc.In International Classification of Diseases, cardiovascular disease is divided into blood circulation diseases, during treatment, how to improve the coronary artery blood supply.
At present, at cerebrovascular and cardiovascular disease, doctor trained in Western medicine adopts heart tonifying more, Drug therapy such as diuresis and blood vessel dilating, especially angiotensin converting enzyme inhibitor, the utilization of vasodilations such as nitrate esters, prolong and saved the life of many patients with heart failure, but this class medicine life-time service can bring serious adverse to human body, as being that the nitroglycerin class preparation of representative is a present cardiovascular disease medicine commonly used with the nitroglycerin, but this type of medicine has bigger side effect, headache for example appears, flushing, tinnitus, dizzy, blood pressure drops, tachycardia etc., life-time service can produce drug resistance, glaucoma in addition, cerebral hemorrhage, the intracranial hypertension patient must avoid usefulness.
In view of Western medicine has absolute advantages aspect treatment cerebrovascular and the cardiovascular disease unlike the antibiotics medicine, and belong to curative effect and inapparent kind, thereby, advantages such as treatment by Chinese herbs cerebrovascular and cardiovascular disease are evident in efficacy to have, reliable and stable, toleration better, have no side effect more and more receive the concern of medical investigator and extensive patients.Also have the Chinese patent medicine of some treatment cerebrovasculars and cardiovascular disease clinically, but wherein much all belong to the kind of " emergency ".Much the medicine of " emergency " all has more serious toxic and side effects, Western medicine the most very, Chinese patent medicine is no exception, only can be used for " emergency ", and should not take for a long time, yet all patients but all need take medicine for a long time, wherein most patients also need take medicine all the life.As the storax pill for treating coronary heart disease for the treatment of coronary heart disease promptly contains Olibanum, Borneolum Syntheticum, Radix Aristolochiae, Lignum Santali Albi, Styrax wet goods composition; Another kind FUFANG DANSHEN PIAN also contains Borneolum Syntheticum etc.These aromatic drug compositions consume the bromhidrosis blood body fluid of hurting sb.'s feelings very much, and clothes are unfavorable on the contrary to the state of an illness for a long time.Simultaneously, cerebrovascular and cardiovascular disease are after first aid, need continue to take effective treatment, and the continuation treatment in that " emergency " just must follow up afterwards as early as possible is only treatment most important, that effect a permanent cure, and clinically, exactly Western medicine lacks effective kind of this respect, and relevant Chinese patent medicine is uncommon yet, particularly treats the Chinese patent medicine of cerebrovascular and cardiovascular disease and Western medicine famine especially simultaneously.
In the cerebrovascular and cardiovascular patient of clinical prescription on individual diagnosis, it is clinical very common symptom that cerebrovascular and cardiovascular diseases have concurrently, and the two also influences each other, and inducement each other.Therefore, exploitation is very necessary to the medicine that cerebrovascular and cardiovascular diseases produce effect simultaneously.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of cerebrovascular and cardiovascular disease; Another object of the present invention is to provide this preparation of drug combination method and purposes.
The invention provides a kind of pharmaceutical composition for the treatment of cerebrovascular and cardiovascular disease, it is the preparation that is prepared from by following materials of weight proportions medicine:
Radix Ginseng 7-13 part, Radix Et Caulis Acanthopanacis Senticosi 10.5-19.5 part, Fructus Hippophae 10.5-19.5 part, Radix Ophiopogonis 10.5-19.5 part, Rhizoma Cyperi 7-13 part, Radix Paeoniae Alba 10.5-19.5 part, Radix Notoginseng 5.6-10.4 part, Radix Achyranthis Bidentatae 10.5-19.5 part, Radix Salviae Miltiorrhizae 10.5-19.5 part, Rhizoma Chuanxiong 7-13 part, Hirudo 2.1-3.9 part.
Further, it is the preparation that is prepared from by following materials of weight proportions medicine:
10 parts of Radix Ginsengs, 15 parts of Radix Et Caulis Acanthopanacis Senticosis, 15 parts of Fructus Hippophaes, 15 parts of Radix Ophiopogonis, 10 parts of Rhizoma Cyperis, 15 parts of the Radix Paeoniae Albas, 8 parts of Radix Notoginseng, 15 parts of Radix Achyranthis Bidentataes, 15 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Chuanxiongs, 3 parts of Hirudos.
Wherein, described preparation is to be active component with the water of the medicated powder of crude drug or crude drug or extractive with organic solvent, adds what pharmaceutically available adjuvant or complementary composition were prepared from.
Wherein, described preparation is an oral formulations.
Further, described oral formulations is powder, granule, pill, hard capsule, soft capsule, tablet, oral liquid or drop pill.
The present invention also provides the preparation method of aforementioned pharmaceutical compositions, and it comprises following operating procedure:
(1) by prescription weight proportion weighting raw materials;
(2) crude drug is extracted with water or organic solvent, extract adds that pharmaceutically available adjuvant or complementary composition are prepared into conventional formulation; Or
(3) crude drug is pulverized, sieved, add that pharmaceutically available adjuvant or complementary composition are prepared into preparation.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment cerebrovascular, cardiovascular disease.
Further, described medicine be treatment cerebral ischemia, cerebral thrombosis, cerebral embolism, apoplexy, coronary heart disease, myocardial ischemia, arrhythmia, heart failure or anginal medicine or, the continuation medicine after adjuvant drug or the first aid.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the preparation anticoagulant.
Further, described anticoagulant is the medicine that prolongs clotting time.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment hypercholesterolemia.
" medication is as using military forces " is the original theory of Chinese medicine of very science, and each medicine tight compatibility all linked with one another as arraying troops for battle in the prescription is its effective means that is better than the Western medicine prescription.The Chinese medicinal formulae theory is thought, each prescription not only needs according to etiology and pathogenesis, selects the suitable appropriate compatibility of medicine, also should meet simultaneously the basic structure of prescription, i.e. the prescription theory of " monarch, minister, help, make ".Promptly, Chinese medicinal formulae is the organic proportioning of Chinese medicine that is based upon on the comprehensive judgement basis of disease pathogenesis, in medical square tube cross too many levels, many target spots and integrate the biological mechanism of regulating, to disease particularly as cerebrovascular and cardiovascular disease the disease of cause of disease complexity, treatment difficulty regulate and control, can obtain than better, the more persistent treatment effect of Western medicine, and this curative effect is to be based upon on the accurate instruction of the original theory of traditional Chinese medical science tradition, and prescription of the present invention is just being followed this principle.
In the pharmaceutical composition of the present invention, with Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Fructus Hippophae QI invigorating, the three is " monarch " medicine; Brain occupies people's height top part, solve brain hematogenous blockage or headache and dizzy, necessary " conducting blood to flow downwards " " subduing the hyperactivity of YANG wind sun ", and the Radix Achyranthis Bidentatae first-selected kind of conducting blood to flow downwards just, the Radix Paeoniae Alba also has the merit of subduing the hyperactivity of YANG wind sun, and these two product can be filled the post of " making " medicine of guide again at this when taking on " minister " medicine; Cerebrovascular and cardiovascular disease are all mended when gas, blood, Tianjin, thus in the prescription of the present invention except that above-mentioned Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Fructus Hippophae QI invigorating, nourish blood with " assistant " medicine Radix Salviae Miltiorrhizae, the Radix Paeoniae Alba again, Radix Ophiopogonis, YIN nourishing and the production of body fluid promoting was set upright to assist a ruler in governing a country principal agent; In addition with the attached circulation of qi promoting of " assistant " medicated incense, to promote and to strengthen the efficacy of a drug of the product of the logical resistance of nourshing blood and promoting blood circulation blood stasis dispellings such as " minister " medicine Radix Notoginseng, Rhizoma Chuanxiong, Hirudo, Radix Salviae Miltiorrhizae, the Radix Paeoniae Alba, Radix Achyranthis Bidentatae, Fructus Hippophae.
The action target spot of Rhizoma Chuanxiong, Hirudo, Radix Notoginseng, Radix Achyranthis Bidentatae is mainly at brain in the side, and the target spot of Radix Salviae Miltiorrhizae, Fructus Hippophae effect is mainly at the heart, and Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Radix Ophiopogonis, Rhizoma Cyperi, the Radix Paeoniae Alba be the brain heart and reaching then, the utilization that is harmonious of three groups of target spots, complement each other, reached the effect that the brain heart is ruled together.
Pharmaceutical composition of the present invention can prolong clotting time, cholesterol reducing level, help to reduce thrombosis and atherosclerotic formation probability, can be used for treating cerebrovascular disease such as cerebral ischemia, cerebral thrombosis and cerebral embolism, cardiovascular disease such as coronary heart disease and hypertension, hyperlipidemia, atherosclerosis, myocardial ischemia, arrhythmia, heart failure, angina pectoris and myocardial infarction, especially for the treatment of the continuation after cerebrovascular, the cardiovascular patient first aid, curative effect is better, for clinical application provides a kind of new selection.
The specific embodiment
Embodiment 1 preparation of drug combination of the present invention
Get Radix Ginseng 10g, Radix Et Caulis Acanthopanacis Senticosi 15g, Fructus Hippophae 15g, Radix Ophiopogonis 15g, Rhizoma Cyperi 10g, Radix Paeoniae Alba 15g, Radix Notoginseng 8g, Radix Achyranthis Bidentatae 15g, Radix Salviae Miltiorrhizae 15g, Rhizoma Chuanxiong 10g, Hirudo 3g; Each flavour of a drug takes by weighing according to quantity, and the intense fire decocting changes slow fire and decocted 30 minutes again, promptly after boiling.
Embodiment 2 preparation of drug combination of the present invention
Get Radix Ginseng 10g, Radix Et Caulis Acanthopanacis Senticosi 15g, Fructus Hippophae 15g, Radix Ophiopogonis 15g, Rhizoma Cyperi 10g, Radix Paeoniae Alba 15g, Radix Notoginseng 8g, Radix Achyranthis Bidentatae 15g, Radix Salviae Miltiorrhizae 15g, Rhizoma Chuanxiong 10g, decoct with water 3 times, each 6-10 times of water with medical material weight decocted 15-30 minute at every turn, merged decocting liquid; The trematodiasis 3g that fetches water again after the pulverizing, adds in the medicinal liquid and stirs evenly, promptly.
Embodiment 3 preparation of drug combination of the present invention
Get Radix Ginseng 7g, Radix Et Caulis Acanthopanacis Senticosi 19.5g, Fructus Hippophae 19.5g, Radix Ophiopogonis 19.5g, Rhizoma Cyperi 13g, Radix Paeoniae Alba 19.5g, Radix Notoginseng 10.4g, Radix Achyranthis Bidentatae 19.5g, Radix Salviae Miltiorrhizae 19.5g, Rhizoma Chuanxiong 13g, Hirudo 3.9g, decoct with water 2 times, each 8-12 times of water with medical material weight, the each decoction 20-40 minute merges decocting liquid, concentrates, add dextrin, soluble starch, wet granulation, drying, promptly.
Embodiment 4 preparation of drug combination of the present invention
Get Radix Ginseng 13g, Radix Et Caulis Acanthopanacis Senticosi 10.5g, Fructus Hippophae 10.5g, Radix Ophiopogonis 10.5g, Rhizoma Cyperi 7g, Radix Paeoniae Alba 10.5g, Radix Notoginseng 5.6g, Radix Achyranthis Bidentatae 10.5g, Radix Salviae Miltiorrhizae 10.5g, Rhizoma Chuanxiong 7g, Hirudo 2.1g, after beating powder, add an amount of microcrystalline Cellulose, behind the mixing, promptly encapsulated.
Below specify beneficial effect of the present invention by testing example.
Clinical (outpatient service) treatment situation of test example 1 pharmaceutical composition of the present invention
(1) patient's selection standard
1, cerebral ischemia: hemiplegia, hemianesthesia appear in the patient, feel to go down, visual disorder, bulbar paralysis, dizzy, headache, tinnitus, dark and dim eyesight, facial numbness, myasthenia of limbs, drinking-water choke cough, one or more symptoms wherein such as babble, can recover normal after sustainable several minutes of these symptoms or a few hours fully, but all in 24 hours, recover normal, but above-mentioned symptom shows effect repeatedly.The brain CT examination, normal or visible lacunar infarction kitchen range.
2, cerebral thrombosis: patient age is higher, risk of stroke factors such as arteriosclerosis and hypertension are arranged or transient ischemic attack was arranged, signs such as premorbid often has that limbs are numb, ineffective, the slurred speech of motion, dizzy, blurred vision, often in sleep or the morbidity in morning, it is movable unable or stiff to suffer from limb, speak ambiguous or aphasia, drinking-water is sent out and is choked, as seen disturbance of consciousness, hemiplegia, aphasia sign obviously and be progressive and increase the weight of state but do not have severe headache, vomiting more.The density regions of the visible cerebral ischemia pathological changes of CT scan.Cerebral angiography shows stricture of artery, obturation and focus abnormal vascular on every side.
3, cerebral embolism: patient age is lighter, does not have above-mentioned cerebral ischemia medical history more, and medical histories such as rheumatic heart disease, atrial fibrillation are often arranged, excited, exert all one's strength, move or activity in fall ill, most headache, vomiting and disturbance of consciousness, hemiplegia, aphasia are normal to be taken place suddenly.CT examination is positive or meet the list of vascularity or multi-section position cerebral tissue low-density or cranium brain nuclear magnetic resonance check and see ischemia or the edema sexually transmitted disease (STD) kitchen range that meets vascularity.
4, coronary heart disease:
Choose according to the diagnostic criteria for coronary heart disease that first national internal medicine academic conference cardiovascular diseases special interest group formulated.
5, myocardial ischemia: the breast abdominal discomfort of similar stomach discomfort occurs, this discomfort has obvious risk factor, as angry or be overburdened with grief etc.Persistent period is in a few minutes or tens minutes, with dull pain, scorching hot and nausea and vomiting sense.Non-precordial pain can appear at back, cervical region, left forearm, wrist, finger, dental bed, throat, even lower limb, and mostly its inducement is fatigue, excitement etc., and is paroxysmal, and taking nitroglycerin can alleviate.Show as the tired of no any reason more, deficient in energy.Through electrocardiogram, coronarography etc., made a definite diagnosis the myocardial ischemia symptom.
6, heart failure: the patient suffers from coronary heart disease, rheumatic heart disease, acute myocardial infarction, DCM (dilated cardiomyopathy), hypertension etc. more, and cardinal symptom has paroxysmal nocturnal dyspnea, distension of jugular vein, lung sound of vomiting sound, cardiac dilatation, acute lung edema, third heart sound gallop, venous pressure increases; Minor symptom has the ankle edema, the nocturnal cough, and movable back dyspnea, hepatomegaly, hydrothorax, vital capacity are reduced to 1/3 of forced vital capacity, tachycardia.Have the binomial cardinal symptom, or have a cardinal symptom and binomial minor symptom person can be diagnosed as heart failure.
7, angina pectoris: show as the squeezing, vexed bloated property or the asphyxiating pain that are positioned at after sternal body epimere or the stage casing more, also may involve most of pareordia, can be radiated to left side shoulder, the preceding inboard of left upper extremity, reach the third finger and little finger of toe, idol can be with dying fear sensation, often force patient to stop action immediately, weight person also perspires.Pain is lasted 1～5 minute, seldom above 15 minutes; Have a rest or contain nitroglycerine tablets, in 1～2 minute (seldom above 5 minutes) be everlasting muscle power tired, excited (angry, anxious, be overexcited), catch cold, be satiated with food, anemia, tachycardia take place during smoking or suffer a shock and also can bring out.Disappear.Pain also can be positioned at inferior segment sternotomy, left pareordia or epigastrium, is radiated to neck, lower jaw, left omoplate portion or right front breast, and pain can be very soon or the uncomfortable stuffy sense of left front breast only arranged.Be diagnosed as angina pectoris by electrocardiogram, stress test etc.
8, arrhythmia: the patient can feel symptom such as heart time-out between cardiopalmus, slow, the irregular heart beating of heart beating, the heart beating, also commonly has that dizziness, uncomfortable in chest, chest pain, out of breath, hyperhidrosis, face are pale, cold extremities, tic, stupor etc.After electrocardiogram is made a definite diagnosis, be arrhythmia.
(2) treatment standard:
Evident in efficacy: patient's subjective symptoms obviously alleviates, and test rating has to a certain degree improvement simultaneously.
Curative effect is obvious: the above-mentioned one (subjective symptoms and test rating) of getting.
Certain effect is arranged: subjective symptoms alleviates to some extent, or index has improvement slightly.
Invalid: symptom remains unchanged, and index not to be improved.
(3) Therapeutic Method:
Get embodiment 1 gained pharmaceutical composition, divide every day and take for three times, the patient takes medicine 3～12 months (decide according to concrete condition such as each conditions of patients weight, age, body constitution) continuously, left and right sides drug withdrawal in about 10 days 1 day (have catch a cold or also temporarily withdraw during new trouble disease such as diarrhoea).
(4) therapeutic outcome:
Treat cerebrovascular and cardiovascular patient 166 examples altogether, cerebrovascular disease patient 95 examples such as wherein cerebral ischemia, cerebral thrombosis, cerebral embolism, cardiovascular patient 71 examples such as coronary heart disease, myocardial ischemia, arrhythmia, heart failure, angina pectoris.Do not wait in 3～12 months through treating, make criterion of therapeutical effect by oneself and observe, among the 95 routine cerebrovascular disease patients, 17 routine effects are remarkable, and 45 routine effects are obvious, and 16 examples have certain effect, 17 routine DeGrains (invalid), total effective rate 82%.In the 71 routine cardiovascular patients, 14 routine effects are remarkable, and 31 routine effects are obvious, and 11 examples have certain effect, 15 routine DeGrains (invalid), total effective rate 78.8%.
The influence of 2 pairs of clotting times of test example
Thrombosis is the surperficial formed fritter of blood flow at inner face exfoliation of cardio-cerebrovascular blood vessel or mend.Thrombosis is made up of insoluble fibrin, sedimentary platelet, the leukocyte that gathers and the erythrocyte that is absorbed in.Yet when suffering from disease such as hypertension, arteriosclerosis, diabetes, vascular endothelial cell is easily impaired, and the thromboplastin that the cell after impaired produces increases, and promotes thrombin to form, and easily brings out thrombosis.After the thrombosis, the blood supply obstacle of cardiovascular and cerebrovascular vessel be can cause, the heart, cerebrovascular disease finally formed.Therefore, prolong clotting time, the formation that slows down thrombosis helps the control to the heart, cerebrovascular disease.
One, experimental technique
60 of SD rats, body weight 180～200g, male and female half and half are divided into 4 groups (concrete grouping sees following table 1 for details), 15 every group at random.Take by weighing medical material by proportioning among the embodiment 1, the intense fire decocting, after changing slow fire after boiling and decocting 30 minutes again, water-bath is concentrated into finite concentration, and the reuse distilled water is made into required solution, and wherein high dose concentration is 3.0g crude drug/ml, and low dosage concentration is 1.5g crude drug/ml.
Pharmaceutical composition high and low dose group of the present invention is pressed 20 times, 10 times of people's dosage respectively, be that 10g crude drug/kg, 5g crude drug/kg give rat oral gavage, aspirin group gastric pours into aspirin 0.18g/kg body weight, blank group is by waiting capacity normal saline to irritate stomach in contrast, every day 1 time, treated continuously 7.Except that the blank group, each treated animal all has death in various degree in experimentation.
Two, experimental result
Treatment is got 10 (only) specimen for every group after finishing at random, 1h after the last administration, and the socket of the eye vein is got blood, drips on clean glass slide, provokes drop of blood with syringe needle in per 5 seconds, and till the blood streak occurring, writing time, experimental result sees the following form 1:
Table 1 pharmaceutical composition of the present invention is to the influence of experimental rat clotting time
| Grouping | The Mus number | Drug dose (g/kg) | Clotting time (S) |
| High dose group | 15→10 | 10.00 | 160.19±76.34 |
| Low dose group | 15→10 | 5.00 | 156.84±79.15 |
| The aspirin group | 15→10 | 0.18 | 179.8±56.21 |
| The blank group | 15→10 | Deng the capacity normal saline | 81.1±33.53 |
The result learns the t check by statistics, pharmaceutical composition high and low dose group of the present invention is compared with the blank group, and its difference significance (P＜0.05) shows that the present invention can prolong the clotting time of laboratory animal, prevent thrombosis, help to reduce the sickness rate of cerebrovascular, cardiovascular disease.
The influence of 3 pairs of hypercholesterolemias of test example
Cholesterol is to be present in the adipose waxy substance of class among zooblast and the human cell, is the indispensable important component of animal tissue cell.But after cholesterol entered ductus arteriosus wall from blood, cholesterol can gather the formation speckle, caused arterial lumen narrow, very easily caused atherosclerosis, and then the cardiac trigger disease.Therefore, hypercholesterolemia is to cause one of most important risk factor of cardiovascular disease, and the early treatment hypercholesterolemia has crucial meaning to preventing and treating cardiovascular disease.
One, experimental technique
60 of SD male rats, body weight 180～200g is divided into 4 groups (concrete grouping sees following table 2 for details), 15 every group at random.Except that the blank group, all the other respectively organize the high lipid food feed rat that all be mixed with 10% cholesterol, 10% Adeps Sus domestica, 0.3% cholic acid every day, feed 15 continuously, and its serum cholesterol is raise, and are made into the hyperlipemia animal model.Pharmaceutical composition of the present invention takes by weighing medical material by embodiment 1 proportioning, and the intense fire decocting is after changing slow fire after boiling and decocting 30 minutes again, water-bath is concentrated into finite concentration, the reuse distilled water is made into required solution, and wherein high dose concentration is 3.0g crude drug/ml, and low dosage concentration is 1.5g crude drug/ml.
When feeding with the rat high lipid food, give pharmaceutical composition of the present invention and irritate stomach: the high and low dose group is pressed 20 times, 10 times of people's dosage respectively, it is 10g crude drug/kg, 5g crude drug/kg feed rat, capacity normal saline such as blank is organized, model group is then pressed are irritated stomach in contrast, every day 1 time, treat (3 week) on the 21st continuously.Except that the blank group, each treated animal all has death in various degree in experimentation.
Two, therapeutic outcome
Treatment is got 10 (only) specimen for every group after finishing at random, and total putting to death detected its serum total cholesterol level with micromethod, the results are shown in following table 2:
Table 2 pharmaceutical composition of the present invention is to the influence of experimental rat serum total cholesterol
| Grouping | The Mus number | Drug dose (g/kg) | Serum total cholesterol (mg/Al) |
| High dose group | 15→10 | 10.00 | 288.3±43.5 |
| Low dose group | 15→10 | 5.00 | 304.6±33.7 |
| Blank group matched group | 15→10 | Deng the capacity normal saline | 259.1±29.4 |
| Model group | 15→10 | Deng the capacity normal saline | 337.2±25.9 |
The result learns the t check by statistics, pharmaceutical composition high and low dose group of the present invention and blank group model group compare, its difference significance (P＜0.05), the cholesterol that shows the present invention's energy intervention experiment animal raises, the hyperlipemia of preventing effect is arranged, reduce atherosclerotic risk, help to reduce the sickness rate of cardiovascular, cerebrovascular disease.
In sum, pharmaceutical composition of the present invention can prolong clotting time, cholesterol reducing level, help to reduce thrombosis and atherosclerotic formation probability, can be used for treating cerebrovascular disease such as cerebral ischemia, cerebral thrombosis and cerebral embolism, cardiovascular disease such as coronary heart disease and hypertension, hyperlipidemia, atherosclerosis, myocardial ischemia, arrhythmia, heart failure, angina pectoris and myocardial infarction, especially for the treatment of the continuation after cerebrovascular, the cardiovascular patient first aid, curative effect is better, for clinical application provides a kind of new selection.
Claims (2)
1. pharmaceutical composition for the treatment of cerebrovascular and cardiovascular disease, it is characterized in that: it is the preparation that is prepared from by following materials of weight proportions medicine: Radix Ginseng 7-13 part, Radix Et Caulis Acanthopanacis Senticosi 10.5-19.5 part, Fructus Hippophae 10.5-19.5 part, Radix Ophiopogonis 10.5-19.5 part, Rhizoma Cyperi 7-13 part, Radix Paeoniae Alba 10.5-19.5 part, Radix Notoginseng 5.6-10.4 part, Radix Achyranthis Bidentatae 10.5-19.5 part, Radix Salviae Miltiorrhizae 10.5-19.5 part, Rhizoma Chuanxiong 7-13 part, Hirudo 2.1-3.9 part.
2. pharmaceutical composition according to claim 1 is characterized in that: it is the preparation that is prepared from by following materials of weight proportions medicine:
10 parts of Radix Ginsengs, 15 parts of Radix Et Caulis Acanthopanacis Senticosis, 15 parts of Fructus Hippophaes, 15 parts of Radix Ophiopogonis, 10 parts of Rhizoma Cyperis, 15 parts of the Radix Paeoniae Albas, 8 parts of Radix Notoginseng, 15 parts of Radix Achyranthis Bidentataes, 15 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Chuanxiongs, 3 parts of Hirudos.
3, pharmaceutical composition according to claim 1 and 2 is characterized in that: described preparation is to be active component with the water of the medicated powder of crude drug or crude drug or extractive with organic solvent, adds what pharmaceutically available adjuvant or complementary composition were prepared from.
4, pharmaceutical composition according to claim 1 is characterized in that: described preparation is an oral formulations.
5, pharmaceutical composition according to claim 4 is characterized in that: described oral formulations is powder, granule, pill, hard capsule, soft capsule, tablet, oral liquid or drop pill.
6, any described preparation of drug combination method of claim 1-5, it is characterized in that: it comprises following operating procedure:
(1) by prescription weight proportion weighting raw materials;
(2) crude drug is extracted with water or organic solvent, extract adds that pharmaceutically available adjuvant or complementary composition are prepared into conventional formulation; Or
(3) crude drug is pulverized, sieved, add that pharmaceutically available adjuvant or complementary composition are prepared into preparation.
7, the purposes of any described pharmaceutical composition of claim 1-5 in the medicine of preparation treatment cerebrovascular, cardiovascular disease.
8, purposes according to claim 7 is characterized in that: described medicine is the continuation medicine after treatment cerebral ischemia, cerebral thrombosis, cerebral embolism, apoplexy, coronary heart disease, myocardial ischemia, arrhythmia, heart failure or anginal medicine, adjuvant drug or the first aid.
9, the purposes of any described pharmaceutical composition of claim 1-5 in the preparation anticoagulant.
10, the purposes of any described pharmaceutical composition of claim 1-5 in the medicine of preparation treatment hypercholesterolemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346271 CN102357195B (en) | 2011-11-04 | 2011-11-04 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346271 CN102357195B (en) | 2011-11-04 | 2011-11-04 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102357195A CN102357195A (en) | 2012-02-22 |
| CN102357195B true CN102357195B (en) | 2013-07-24 |
Family
ID=45582612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110346271 Expired - Fee Related CN102357195B (en) | 2011-11-04 | 2011-11-04 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102357195B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417591B (en) * | 2012-05-24 | 2016-02-24 | 四川济生堂药业有限公司 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
| CN103505489A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition containing Sichuan lovage rhizome and preparation method of composition |
| CN103505488A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition |
| CN104189288B (en) * | 2014-09-16 | 2017-10-27 | 张玉清 | A kind of Chinese medicine composition for treating myocardial infarction and its application |
| CN109925398A (en) * | 2017-12-18 | 2019-06-25 | 唐东 | It is a kind of to treat hypertension Chinese materia medica preparation |
-
2011
- 2011-11-04 CN CN 201110346271 patent/CN102357195B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 中医治疗冠心病集析;杜昱林等;《中医药学刊》;20050310;第23卷(第03期);561-563 * |
| 杜昱林等.中医治疗冠心病集析.《中医药学刊》.2005,第23卷(第03期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102357195A (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104606513B (en) | A kind of Chinese medicine for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN102512470B (en) | Pharmaceutical composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application | |
| CN108261505A (en) | A kind of drug of logical stalkization bolt and preparation method thereof | |
| CN103705789A (en) | Pharmaceutical composition for treating cerebral hemorrhage | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN112741887B (en) | Traditional Chinese medicine composition for treating depression | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN102552715B (en) | Chinese medicinal composition, medicine containing Chinese medicinal composition and preparation method of medicine | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN102512562B (en) | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method and applications thereof | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
| CN104352973A (en) | Chinese patent medicine for postpartum depression | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN103191187A (en) | Uses of different positions of Salvia miltiorrhiza Bunge and Panax Notoginseng and combinations thereof in smooth muscle cell proliferation inhibition and coronary artery restenosis control | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN102335304B (en) | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof | |
| CN101244134B (en) | New purpose of naodesheng extract for treating diabetes complication | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN106389702A (en) | Traditional Chinese medicine for recovering symptoms of gynecological and obstetric surgery and preparation method of traditional Chinese medicine | |
| CN101406666B (en) | Chinese medicine for treating coronary heart disease and angina pectoris, and preparation method and use thereof | |
| CN105125886A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130724 Termination date: 20161104 |